Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2023 Jan;29(1):10-18.
doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21.

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Fareed Khawaja  1 , Genovefa Papanicolaou  2 , Sanjeet Dadwal  3 , Steven A Pergam  4 , John R Wingard  5 , Zeinab El Boghdadly  6 , Maheen Z Abidi  7 , Alpana Waghmare  8 , Zainab Shahid  9 , Laura Michaels  10 , Joshua A Hill  4 , Mini Kamboj  2 , Michael Boeckh  4 , Jeffery J Auletta  11 , Roy F Chemaly  12
Affiliations
Practice Guideline

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology

Fareed Khawaja et al. Transplant Cell Ther. 2023 Jan.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19-related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.

Keywords: Adenoviral vector vaccine; Bone marrow transplant; CAR T-cell; COVID-19; Chimeric antigen receptor T-cell; Coronavirus disease 2019; Hematopoietic cell transplant; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccine safety; mRNA vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2. Science. 2022;375:1116–1121. - PMC - PubMed
    1. Coll E, Fernandez-Ruiz M, Sanchez-Alvarez JE, et al. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2021;21:1825–1837. - PMC - PubMed
    1. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185–ee93. - PMC - PubMed
    1. Pinana JL, Martino R, Garcia-Garcia I, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21. - PMC - PubMed
    1. Vicent MG, Martinez AP, Trabazo Del Castillo M, et al. COVID-19 in pediatric hematopoietic stem cell transplantation: the experience of Spanish Group of Transplant (GETMON/GETH) Pediatr Blood Cancer. 2020;67:e28514. - PMC - PubMed

Publication types

Substances